Table 3.
Prevalence of platelet refractoriness based on platelet increment (PI) and different cutoffs for the corrected count index (CCI), in different patient subgroups and according to the platelet product types and the time interval between platelet transfusion and the posttransfusion platelet count.
| Prevalence of platelet refractoriness | ||
|---|---|---|
| PI < 10000 × 106/L | CCI <5000 | |
| All patients (N = 259) | 54.8% | 57.0% |
| Admission category | ||
| Medical (N = 220) | 56.8% | 58.5% |
| Surgical (N = 30) | 53.3% | 60% |
| Trauma (N = 9) | 11.1% | 11.1% |
| Admitting service | ||
| Internal medicine (N = 74) | 54.5% | 56.8% |
| Hematology/oncology (N = 72) | 58.9% | 56.9% |
| Hepatology/liver transplant (N = 46) | 69.6% | 71.7% |
| General surgery (N = 37) | 43.2% | 45.9% |
| Splenomegaly∗ (N = 65) | 61.5% | 64.6% |
| No splenomegaly (N = 113) | 46.0% | 50% |
| Platelet product type | ||
| Apheresis (N = 139∗∗) | 62.6% | 64% |
| Apheresis-irradiated (N = 195∗∗) | 46.9% | 47.7% |
| Pooled (N = 747∗∗) | 59.1% | 61.6% |
| Pooled-irradiated (N = 179∗∗) | 47.3% | 50.3% |
| Mixed∗∗∗ (N = 90∗∗) | 48.4% | 65.6% |
| Time interval between platelet transfusion and the posttransfusion platelet count | ||
| <3 hours (N = 319∗∗) | 55.4% | 57.4% (63.9% for CCI <7500) |
| 3–6 hours (N = 583∗∗) | 51.3% | 55.2% |
| 7–12 hours (N = 292∗∗) | 61.0% | 63.4% |
| >12 hours (N = 113∗∗) | 60.3% | 63.7% (61.1% for CCI <4500) |
∗Spleen size was known in 178 patients. For the calculation of percentages, only valid observations are used in the numerator and denominator. ∗∗Transfusion episodes. ∗∗∗Mixed indicates aggregate transfusions that were derived from transfusions with 2 or more different platelet products.